Sunshine Lake Pharma Co., Ltd.
Research Sunshine Lake Pharma Co., Ltd. (6887.HK) on Bullrun: market cap HKD 22.09B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker6887.HK
- ExchangeHK
- CountryChina
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyHKD
- Market capHKD 22.09B
- Financial periodFY2025
- RevenueCNY 4.82B
- Revenue growth19.8%
- Net incomeCNY 272.44M
- Free cash flowCNY 228.28M
- Gross margin76.5%
Valuation Snapshot
latest market cap is HKD 22.09B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CNY 4.82B | CNY 272.44M | CNY 228.28M | 76.5% | n/a | CNY 1.49B | CNY 4.68B | CNY 4.34B |
| FY2024 | CNY 4.02B | -CNY 207.43M | -CNY 724.67M | 76.1% | -0.46 | CNY 1.48B | CNY 4.62B | CNY 344.15M |
| FY2023 | CNY 6.39B | CNY 184.92M | CNY 782.88M | 79.5% | 0.41 | CNY 1.92B | CNY 5.35B | CNY 327.92M |
| FY2022 | CNY 3.81B | -CNY 1.21B | CNY 143.73M | 76.6% | -2.65 | CNY 971.51M | CNY 6.28B | -CNY 3.69B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | HKD 22.09B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 HKD.
About Sunshine Lake Pharma Co., Ltd.
Sunshine Lake Pharma Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products for the treatment of infectious diseases, chronic diseases, and oncology. It offers Kewei for the treatment of influenza; Dongweien and Dongyinghe for the treatment of hepatitis C. The company also engages in the import, export, wholesale, retail, and distribution of pharmaceutical products, intermediates, and active pharmaceutical ingredients; product quality inspection;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Sunshine Lake Pharma Co., Ltd.'s market cap?
Sunshine Lake Pharma Co., Ltd.'s market capitalization is HKD 22.09B.
What does Sunshine Lake Pharma Co., Ltd. do?
Sunshine Lake Pharma Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products for the treatment of infectious diseases, chronic diseases, and oncology. It offers Kewei for the treatment of influenza; Dongweien and Dongyinghe for the treatment of hepatitis C.